The US Department of Veterans Affairs Science and Health Initiative to Combat Infectious and Emerging Life-Threatening Diseases (VA SHIELD): A Biorepository Addressing National Health Threats
Authors:
- John B HarleyJHJohn B Harley
- Saiju PyarajanSPSaiju Pyarajan
- Elizabeth S PartanEPElizabeth S Partan
- Lauren EpsteinLELauren Epstein
- Jason A WertheimJWJason A Wertheim
- Abhinav DiwanAbhinav Diwan
- Christopher W WoodsCWChristopher W Woods
- Victoria DaveyVDVictoria Davey
- Sharlene BlairSBSharlene Blair
- Dennis H ClarkDCDennis H Clark
- Kenneth M KaufmanKKKenneth M Kaufman
Open Access
- 1 December 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 9 (12) , ofac641
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has demonstrated the need to share data and biospecimens broadly to optimize clinical outcomes for US military Veterans. Methods: In response, the Veterans Health Administration established VA SHIELD (Science and Health Initiative to Combat Infectious and Emerging Life-threatening Diseases), a comprehensive biorepository of specimens and clinical data from affected Veterans to advance research and public health surveillance and to improve diagnostic and therapeutic capabilities. Results: VA SHIELD now comprises 12 sites collecting de-identified biospecimens from US Veterans affected by SARS-CoV-2. In addition, 2 biorepository sites, a data processing center, and a coordinating center have been established under the direction of the Veterans Affairs Office of Research and Development. Phase 1 of VA SHIELD comprises 34 157 samples. Of these, 83.8% had positive tests for SARS-CoV-2, with the remainder serving as contemporaneous controls. The samples include nasopharyngeal swabs (57.9%), plasma (27.9%), and sera (12.5%). The associated clinical and demographic information available permits the evaluation of biological data in the context of patient demographics, clinical experience and management, vaccinations, and comorbidities. Conclusions: VA SHIELD is representative of US national diversity with a significant potential to impact national healthcare. VA SHIELD will support future projects designed to better understand SARS-CoV-2 and other emergent healthcare crises. To the extent possible, VA SHIELD will facilitate the discovery of diagnostics and therapeutics intended to diminish COVID-19 morbidity and mortality and to reduce the impact of new emerging threats to the health of US Veterans and populations worldwide.Keywords
This publication has 12 references indexed in Scilit:
- Genetic Loci Associated With COVID-19 Positivity and Hospitalization in White, Black, and Hispanic Veterans of the VA Million Veteran ProgramFrontiers in Genetics, 2022
- APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran ProgramJAMA Internal Medicine, 2022
- Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans — Five Veterans Affairs Medical Centers, United States, February 1–September 30, 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- Attitudes and Intentions of US Veterans Regarding COVID-19 VaccinationJAMA Network Open, 2021
- Adapting the Surveillance Platform for Enteric and Respiratory Infectious Organisms at United States Veterans Affairs Medical Centers (SUPERNOVA) for COVID-19 Among Hospitalized Adults: Surveillance ProtocolFrontiers in Public Health, 2021
- Phenome-wide association of 1809 phenotypes and COVID-19 disease progression in the Veterans Health Administration Million Veteran ProgramPLOS ONE, 2021
- Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10 131 US Veterans With SARS-CoV-2 InfectionJAMA Network Open, 2020
- The UK Biobank resource with deep phenotyping and genomic dataNature, 2018
- Million Veteran Program: A mega-biobank to study genetic influences on health and diseaseJournal of Clinical Epidemiology, 2016
- Biobanking and translation of human genetics and genomics for infectious diseasesApplied & Translational Genomics, 2014